• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Hims & Hers Health Inc.

    2/24/25 4:45:56 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email
    S-8 1 s-8february2025.htm S-8 Document

    As filed with the Securities and Exchange Commission on February 24, 2025
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ---------------------------------------------

    FORM S-8
    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
    ---------------------------------------------

    HIMS & HERS HEALTH, INC.
    (Exact name of registrant as specified in its charter)
    ---------------------------------------------

    Delaware
    98-1482650
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)
    2269 Chestnut Street, #523
    San Francisco, California
    94123
    (Address of Principal Executive Offices)
    (Zip Code)

    HIMS & HERS HEALTH, INC. 2020 EQUITY INCENTIVE PLAN

    (Full title of the plan)

    Andrew Dudum
    Chief Executive Officer
    Hims & Hers Health, Inc.
    2269 Chestnut Street, #523
    San Francisco, California 94123
    Tel.: (415) 851-0195
    (Name and address, including zip code, and telephone number, including area code, of agent for service)
    ---------------------------------------------

    Copies to:
    Jeffrey R. Vetter
    Alexa Belonick
    Elena Vespoli
    Gunderson Dettmer Stough Villeneuve
    Franklin & Hachigian, LLP
    550 Allerton Street
    Redwood City, California 94063
    Tel: (650) 463-5335
    Fax: (650) 618-3286

    Soleil Boughton
    Chief Legal Officer
    Hims & Hers Health, Inc.
    2269 Chestnut Street, #523
    San Francisco, California 94123
    Tel.: (415) 851-0195




    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer
    x
    Accelerated filer
    o
    Non-accelerated filer
    o
    Smaller reporting company
    o
    Emerging growth company
    o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

    ---------------------------------------------
    The Registration Statement shall become effective upon filing in accordance with Rule 462 under the Securities Act.

    ---------------------------------------------------------------------------------------------------------------------





    EXPLANATORY NOTE

    Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended (the “1933 Act”), this Registration Statement is filed by Hims & Hers Health, Inc. (the “Registrant”) for the purpose of registering additional shares of Class A common stock, par value $0.0001 per share, of the Company (the “Class A Common Stock”) under the 2020 Equity Incentive Plan pursuant to the provision of such plan that provides for automatic annual increases in the number of shares reserved for issuance thereunder. This Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on March 29, 2021 (File No. 333-254825), March 9, 2022 (File No. 333-263391), February 28, 2023 (File No. 333-270115), and February 26, 2024 (File No. 333-277372) to the extent not superseded hereby.





    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of this Registration Statement is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to plan participants as required by Rule 428(b)(1).






    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents previously filed by the Registrant with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

    (1) the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on February 24, 2025; and

    (2) the description of the Registrant’s Class A Common Stock contained in Exhibit 4.2 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Commission on February 27, 2023, including any amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents (such documents, and the documents enumerated above, being hereinafter referred to as “Incorporated Documents”).

    Any statement contained in an Incorporated Document shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed Incorporated Document modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information disclosed by the Registrant under Items 2.02 or 7.01 of any current report on Form 8-K, including the related exhibits under Item 9.01, that the Registrant may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a court to award, or a corporation’s board of directors to grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section 145 of the Delaware General Corporation Law are sufficiently broad to permit indemnification under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended (the “Securities Act”).
    As permitted by the Delaware General Corporation Law, our Certificate of Incorporation contains provisions that eliminate the personal liability of our directors for monetary damages for any breach of fiduciary duties as a director, except liability for the following:




    •any breach of the director’s duty of loyalty to the Registrant or its stockholders;
    •acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
    •under Section 174 of the Delaware General Corporation Law (regarding unlawful dividends and stock purchases); or
    •any transaction from which the director derived an improper personal benefit.

    As permitted by the Delaware General Corporation Law, our Bylaws provide that:

    •we are required to indemnify our directors and officers to the fullest extent permitted by the Delaware General Corporation Law, subject to very limited exceptions;
    •we may indemnify other employees and agents as set forth in the Delaware General Corporation Law;
    •we are required to advance expenses, as incurred, to our directors and officers in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and
    •the rights conferred in the bylaws are not exclusive.

    We have entered, and intend to continue to enter into separate indemnification agreements with our current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Certificate of Incorporation and Bylaws and to provide additional procedural protections. At present, there is no pending litigation or proceeding involving a director, executive officer or employee for which indemnification is sought. The indemnification provisions in the Certificate of Incorporation, Bylaws and the indemnification agreements between us and our directors and executive officers may be sufficiently broad to permit indemnification of our directors and executive officers for liabilities arising under the Securities Act.

    We have directors’ and officers’ liability insurance for securities matters.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    Exhibit No.
    Description
    4.1
    Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 26, 2021).
    4.2
    Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on January 26, 2021).
    4.3
    Hims & Hers Health, Inc. 2020 Equity Incentive Plan and forms of agreement thereunder (incorporated by reference to Exhibit 10.4 to the Company’s Annual Report on Form 10-K filed with the SEC on February 27, 2023).
    *5.1
    Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.
    *23.1
    Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included as part of Exhibit 5.1 hereto).
    *23.2
    Consent of KPMG LLP, independent registered public accounting firm of the Registrant.
    *24.1
    Powers of Attorney (included in the signature page to this Registration Statement).
    *107
    Filing Fee Table.
    _______________
    *Filed herewith.





    Item 9. Undertakings.

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.






    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on February 26, 2024.


    HIMS & HERS HEALTH, INC.
    By:
    /s/ Andrew Dudum
    Name:
    Andrew Dudum
    Title:
    Chief Executive Officer
    (Principal Executive Officer)


    POWER OF ATTORNEY

    KNOW ALL PERSON BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Andrew Dudum and Oluyemi Okupe, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities to sign, execute and file all amendments (including, without limitation, post-effective amendments) to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, and his or her substitute or substitutes may lawfully do or case to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    SignatureTitleDate
    /s/ Andrew Dudum
    Chief Executive Officer and DirectorFebruary 24, 2025
    Andrew Dudum
    (Principal Executive Officer)
    /s/ Oluyemi Okupe
    Chief Financial OfficerFebruary 24, 2025
    Oluyemi Okupe
    (Principal Financial Officer)
    /s/ Irene Becklund
    Senior Vice President and ControllerFebruary 24, 2025
    Irene Becklund(Principal Accounting Officer)
    /s/ Deborah M. AutorDirectorFebruary 24, 2025
    Deborah M.Autor
    /s/ Patrick Carroll, M.D.
    DirectorFebruary 24, 2025
    Patrick Carroll, M.D.



    /s/ Delos Cosgrove, M.D.
    DirectorFebruary 24, 2025
    Delos Cosgrove, M.D.
    /s/ Anja ManuelDirectorFebruary 24, 2025
    Anja Manuel
    /s/ Christopher Payne
    DirectorFebruary 24, 2025
    Christopher Payne
    /s/ Christiane PendarvisDirectorFebruary 24, 2025
    Christiane Pendarvis
    /s/ Andrea PerezDirectorFebruary 24, 2025
    Andrea Perez
    /s/ Kåre SchultzDirectorFebruary 24, 2025
    Kåre Schultz
    /s/ David Wells
    DirectorFebruary 24, 2025
    David Wells

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    10/21/2025Sector Weight
    KeyBanc Capital Markets
    6/23/2025Buy → Hold
    Needham
    6/4/2025$61.00 → $65.00Buy
    Needham
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    More analyst ratings

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026

    San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Weight management concerns should be evaluated by a qualified healthcare professional. Hims GLP-1 Weight Loss is a prescription-only medication program available exclusively through licensed physician consultation. This content does not diagnose, treat, cure, or prevent any disease. Prescription approval is not guaranteed. If you purchase through links in this article, a commission may be earned at no additional cost to you. Purpose and Scope This release is an informational overview of publicly available disclosures for Hims GLP-1 Weight Loss

    2/5/26 8:51:30 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205680502/en/ By leveraging nearly a decade of infrastructure investment to drive radical affordability, Hims & Hers is making personalized care more accessible than ever.

    2/5/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

    The company will offer access to Galleri®, an innovative blood test from GRAIL, Inc. that screens for more than 50 types of cancer Today, Hims & Hers Health, Inc. (NYSE:HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®, a simple cancer screening blood test that can detect a signal for 50+ types of cancer even before symptoms appear1. This multi-cancer early detection (MCED) test combines Hims & Hers' scale with GRAIL's innovative cancer screening technology to dramatically increase access to proactive care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026

    2/4/26 9:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Hims & Hers Health Inc.

    SCHEDULE 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    2/13/26 5:32:39 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 144 filed by Hims & Hers Health Inc.

    144 - Hims & Hers Health, Inc. (0001773751) (Subject)

    12/22/25 5:00:50 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    11/17/25 8:04:04 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Hims & Hers Health with a new price target

    Evercore ISI initiated coverage of Hims & Hers Health with a rating of In-line and set a new price target of $33.00

    1/12/26 8:13:43 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Barclays initiated coverage on Hims & Hers Health with a new price target

    Barclays initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $48.00

    12/9/25 8:50:15 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    KeyBanc Capital Markets initiated coverage on Hims & Hers Health

    KeyBanc Capital Markets initiated coverage of Hims & Hers Health with a rating of Sector Weight

    10/21/25 7:20:02 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Okupe Oluyemi exercised 5,262 shares at a strike of $5.01 and sold $139,108 worth of shares (5,262 units at $26.44) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    2/4/26 4:13:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 9,067 shares at a strike of $6.27 and sold $275,114 worth of shares (9,067 units at $30.34) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/21/26 4:23:35 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Chief Financial Officer Okupe Oluyemi exercised 5,986 shares at a strike of $9.16 and sold $306,453 worth of shares (9,070 units at $33.79), decreasing direct ownership by 3% to 91,617 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    1/7/26 4:16:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report fourth quarter and full year 2025 financial results after the market closes on Monday, February 23, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the c

    2/2/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

    Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3 2025 Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $307 million to $317 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a shareholder letter that is posted at investors.hims.com. "This quarter we continued to prove that our vision of helping tens of mill

    11/3/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 3, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a missio

    10/13/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

    Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

    5/8/25 6:50:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

    Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

    5/5/25 9:01:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care